Endo Pharma ends collaboration on back pain drug – BusinessWeek
Endo Pharma ends collaboration on back pain drug BusinessWeek Endo Pharmaceuticals Holdings Inc. said Wednesday that it is ending a partnership on an experimental back pain drug.
Read more here:
Endo Pharma ends collaboration on back pain drug – BusinessWeek
Newron Pharma’s neuropathic pain drug fails in Serena study on NLBP patients – pharmabiz.com
Posted in: Back Pain News Tags: difference-between, least-moderate, neuropathic, newron-pharma, nlbp, pain-drug, pharma, study-on-nlbp
Newron Pharma's neuropathic pain drug fails in Serena study on NLBP patients pharmabiz.com … in patients with at least moderate Neuropathic Low Back Pain (NLBP) failed to show any significant difference between ralfinamide and placebo.
See original here:
Newron Pharma’s neuropathic pain drug fails in Serena study on NLBP patients – pharmabiz.com
Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin (PRWeb via Yahoo! News)
Posted in: Back Pain News Tags: cobroxin, fourth, nutra-pharma, otc, pain-reliever, pharma, quarter-ending, sales-totaling, the-fourth
Nutra Pharma has announced that its over-the-counter (OTC) pain reliever, Cobroxin, has generated sales totaling $583,955 for the fourth quarter ending December 31, 2009.
See the original post here:
Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin (PRWeb via Yahoo! News)